BioCentury | Nov 4, 2013
Strategy

Teva blinks

With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday,...
BC Innovations | Mar 22, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); cognitive dysfunction Microtubule-associated protein-t (MAPT; TAU; FTDP-17) Transgenic mouse studies suggest microtubule-stabilizing compounds that penetrate the blood brain barrier could help treat...
BC Innovations | Dec 8, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Annexin A1 (ANXA1) Studies in mice identified an ANXA1-targeted peptide that could help treat cancer. In mice with tumors, injection of a phage library...
BioCentury | Mar 21, 2011
Product Development

Safe to move forward vs. Hsp90

Based on recently reported Phase II data, Synta Pharmaceuticals Corp. thinks it has the first Hsp90 inhibitor to have both meaningful cancer activity and a clean safety profile. It plans to start a Phase IIb/III...
BioCentury | Feb 28, 2011
Emerging Company Profile

Karyopharm: Shushing the usher

In the battle with the human body's natural defense mechanisms, one of the favorite tricks of tumor cells is to use karyopherins to usher tumor suppressor proteins outside the nucleus where they can no longer...
BC Innovations | Oct 28, 2010
Targets & Mechanisms

Stabilizing tauopathies

Researchers at the University of Pennsylvania have found that low doses of the microtubule stabilizer epothilone D, a failed cancer compound from the Kosan Biosciences unit of Bristol-Myers Squibb Co. , could have utility in neurodegenerative...
BC Innovations | Oct 21, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); cognitive dysfunction Tubulin Studies in mice suggest that microtubule-stabilizing compounds that penetrate the blood-brain barrier could help treat AD. In a mouse...
BC Innovations | Aug 5, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Heat shock protein 90 (Hsp90); mitogen-activated protein kinase kinase (MEK) In vitro studies suggest that combining inhibitors of Hsp90 and MEK could help...
BC Week In Review | Jul 19, 2010
Company News

Biotica, Bristol-Myers deal

Biotica acquired a type II polyketide chemical library and IP related to a bioengineering technique from Bristol-Myers. Biotica said the deal strengthens its polyketide engineering platform and the IP complements its lead optimization and heterologous...
BC Innovations | Dec 3, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma (BCL) B cell CLL/lymphoma 6 (BCL6); heat shock protein 90 (Hsp90) A study in mice suggests that Hsp90 inhibitors could help treat...
Items per page:
1 - 10 of 283
BioCentury | Nov 4, 2013
Strategy

Teva blinks

With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday,...
BC Innovations | Mar 22, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); cognitive dysfunction Microtubule-associated protein-t (MAPT; TAU; FTDP-17) Transgenic mouse studies suggest microtubule-stabilizing compounds that penetrate the blood brain barrier could help treat...
BC Innovations | Dec 8, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Annexin A1 (ANXA1) Studies in mice identified an ANXA1-targeted peptide that could help treat cancer. In mice with tumors, injection of a phage library...
BioCentury | Mar 21, 2011
Product Development

Safe to move forward vs. Hsp90

Based on recently reported Phase II data, Synta Pharmaceuticals Corp. thinks it has the first Hsp90 inhibitor to have both meaningful cancer activity and a clean safety profile. It plans to start a Phase IIb/III...
BioCentury | Feb 28, 2011
Emerging Company Profile

Karyopharm: Shushing the usher

In the battle with the human body's natural defense mechanisms, one of the favorite tricks of tumor cells is to use karyopherins to usher tumor suppressor proteins outside the nucleus where they can no longer...
BC Innovations | Oct 28, 2010
Targets & Mechanisms

Stabilizing tauopathies

Researchers at the University of Pennsylvania have found that low doses of the microtubule stabilizer epothilone D, a failed cancer compound from the Kosan Biosciences unit of Bristol-Myers Squibb Co. , could have utility in neurodegenerative...
BC Innovations | Oct 21, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); cognitive dysfunction Tubulin Studies in mice suggest that microtubule-stabilizing compounds that penetrate the blood-brain barrier could help treat AD. In a mouse...
BC Innovations | Aug 5, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Heat shock protein 90 (Hsp90); mitogen-activated protein kinase kinase (MEK) In vitro studies suggest that combining inhibitors of Hsp90 and MEK could help...
BC Week In Review | Jul 19, 2010
Company News

Biotica, Bristol-Myers deal

Biotica acquired a type II polyketide chemical library and IP related to a bioengineering technique from Bristol-Myers. Biotica said the deal strengthens its polyketide engineering platform and the IP complements its lead optimization and heterologous...
BC Innovations | Dec 3, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma (BCL) B cell CLL/lymphoma 6 (BCL6); heat shock protein 90 (Hsp90) A study in mice suggests that Hsp90 inhibitors could help treat...
Items per page:
1 - 10 of 283